TP53 and bladder transitional cell carcinoma: In this study, we assessed the mutational landscape as well as the prognostic significance of concurrent <i>TERT</i>p and <i>TP53</i> mutations in a cohort of bladder urothelial carcinoma patients.<h4>Methods</h4>Using data from the cBioPortal database, we retrospectively analysed primary bladder urothelial carcinoma cases profiled with the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assays.